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Idiopathic pulmonary ﬁbrosis (IPF) is a fatal lung disorder of unknown etiology characterized
by accumulation of lung ﬁbroblasts and extracellular matrix deposition, ultimately leading
to compromised tissue architecture and lung function capacity. IPF has a heterogeneous
clinical course; however the median survival after diagnosis is only 3–5 years. The
pharmaceutical and biotechnology industry has made many attempts to ﬁnd effective
treatments for IPF, but the disease has so far deﬁed all attempts at therapeutic intervention.
Clinical trial failures may arise for many reasons, including disease heterogeneity, lack of
readily measurable clinical end points other than overall survival, and, perhaps most of
all, a lack of understanding of the underlying molecular mechanisms of the progression
of IPF. The precise link between inﬂammation and ﬁbrosis remains unclear, but it appears
that immune cells can promote ﬁbrosis by releasing ﬁbrogenic factors. So far, however,
therapeutic approaches targeting macrophages, neutrophils, or lymphocytes have failed to
alter disease pathogenesis. A new cell to garner research interest in ﬁbrosis is the mast
cell. Increased numbers of mast cells have long been known to be present in pulmonary
ﬁbrosis and clinically correlations betweenmast cells and ﬁbrosis have been reported. More
recent data suggests that mast cells may contribute to the ﬁbrotic process by stimulating
ﬁbroblasts resident in the lung, thus driving the pathogenesis of the disease. In this review,
we will discuss the mast cell and its physiological role in tissue repair and remodeling, as
well as its pathological role in ﬁbrotic diseases such as IPF, where the process of tissue
repair and remodeling is thought to be dysregulated.
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INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a lethal lung disorder of
unknown etiology. With a median survival of 3–5 years and an
increasing incidence (Dempsey, 2006; Navaratnam et al., 2013)
IPF is attracting much research attention. Histologically, IPF
is characterized by heterogeneity: areas of normal parenchyma
are interspersed with areas of paraseptal and subpleural ﬁbrosis
(Raghuet al.,2011). Theﬁbrotic process is oftendeﬁned as an aber-
rant wound healing response, involving dysregulated tissue repair
and remodeling (Wynn, 2011). There is epithelial damage, inﬂam-
matory cell inﬁltration, elevated pro-ﬁbrotic cytokine expression,
formation of ﬁbroblastic foci, and increased extracellular matrix
(ECM) deposition (Wilson andWynn, 2009; Figure 1).
The precise link between inﬂammation and ﬁbrosis remains
unclear, but it appears that immune cells can promote ﬁbro-
sis by releasing ﬁbrogenic factors (Stramer et al., 2007). So far,
however, therapeutic approaches targeting macrophages, neu-
trophils, or lymphocytes have failed to alter disease pathogenesis.
A new cell to garner research interest in ﬁbrosis is the mast cell.
Indeed, increased numbers of mast cells have long been known
to be present in pulmonary ﬁbrosis (Kawanami et al., 1979), and
clinically correlations between mast cells and ﬁbrosis have been
reported (Metcalfe et al., 1997). More recent data suggests that
mast cells may drives the ﬁbrotic process by stimulating ﬁbrob-
lasts resident in the lung (Wygrecka et al., 2013), thus driving the
pathogenesis of the disease. In this review, we will discuss the mast
cell and its physiological role in tissue repair and remodeling, as
well as its pathological role in ﬁbrotic diseases such as IPF, where
tissue repair and remodeling are dysregulated (Wynn,2011). Addi-
tionally, while the inﬂammatory roles of mast cells in asthma and
atopic dermatitis are well characterized (Dougherty et al., 2010;
Andersson et al., 2011a), the potential role of mast cells in medi-
ating the tissue remodeling components of these diseases is also
discussed.
MAST CELL BIOLOGY
Mast cells are innate immune cells, originally named by Paul
Ehrlich in 1878 on the basis of their granular histological staining
with aniline dyes. Both human and rodent mast cells origi-
nate from hematopoietic stem cells (HSCs) in the bone marrow,
which give rise to common myeloid progenitors that can subse-
quently differentiate into mast cell precursors (Rodewald et al.,
1996; Austen and Boyce, 2001; Franco et al., 2010). A number of
publications suggest that mast cells could also arise from a shared
basophil/mast cell progenitor. These cells had until recently only
been identiﬁed in the mouse spleen (Arinobu et al., 2005), but
have now also been identiﬁed in mouse bone marrow (Qi et al.,
2013). In humans, common progenitor cells have been identiﬁed
in the context of disease, for example in patients with myelo-
proliferative diseases (Zucker-Franklin, 1980). The exact origin
of mast cells remains controversial, and others suggest that mast
cells diverge from basophils relatively early in their differentia-
tion (Chen et al., 2005; Mukai et al., 2012). Mast cells circulate
as somewhat immature cells (Kitamura et al., 1979) and undergo
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FIGURE 1 | Schematic outlining the key mast cell mediators
contributing to fibrosis, the effector cells that generate
transforming growth factor (TGF)β and interleukin (IL)-13 and the
enzymes associated with idiopathic pulmonary fibrosis (IPF).
Multiple cell types are found at sites of lung ﬁbrosis. Many are
direct producers of extracellular matrix (ECM), or indirectly promote
the generation and deposition of aberrant matrix. Mast cells
generate pro-ﬁbrotic mediators including tryptase, chymase, and
chemokines that promote ﬁbroblast activation. This ﬁgure is adapted
from Clarke et al. (2013).
ﬁnal maturation upon entry into peripheral tissues. They reside
within most tissues of the body, and are notable at sites that act as
barriers to the external environment such as the skin, lung, and the
intestine.
The phenotypic heterogeneity of mast cells is well known,
with two major subsets being recognized. In rodents, the two
subsets have different anatomical localization and expression pat-
tern of proteases. Connective tissue mast cells (CTMCs), as the
name implies, are mainly located in the connective tissues of the
intestinal submucosa, the peritoneal cavity and surrounding blood
vessels, and in the skin. These cells express both chymases and
tryptases. In contrast, mucosal mast cells (MMCs) are usually
found in the mucosal tissues of the lung and intestine and mainly
express chymases (Gurish and Austen, 2012). In humans, the two
subtypes of mast cells can similarly be characterized on the basis
of their protease expression: MCT express tryptase only whereas
MCTC contain both tryptase and chymase. The former appear to
correspond to the murine mucosal type mast cell and the latter to
CTMCs (Irani et al., 1986; Welle, 1997).
In addition to differences in protease content and anatomi-
cal localization, mast cells are also heterogeneous with regard to
receptor expression and mediator release, and in their functional
responses to various stimuli (Lowman et al., 1988; Bradding et al.,
1995; Andersson et al., 2009). Some of themorewell-characterized
receptors are those required for the survival and/or activation of
mast cells. Activation of the receptor c-kit is required for the sur-
vival, proliferation and differentiation of allmast cells via its ligand
stem cell factor (SCF).Awell characterizedmechanismof mast cell
activation is through aggregation of FcεR1, the high afﬁnity IgE
receptor (Razin et al., 1983), although stimulation of other recep-
tors, such as TLRs and the IL-33 receptor ST2 can also result in
mast cell activation (Smith and Parikh, 1999;Varadaradjalou et al.,
2003).
Upon activation, mast cells secrete an array of biologically
active mediators (reviewed in Gilﬁllan and Beaven, 2011). Rapid
mediator release occurs withinminutes from pre-formed granules
which can be completely emptied through exocytosis or partly
emptied, but preserved for renewed release. Granules contain
histamine, lipid mediators, proteoglycans, and proteases like chy-
mases, tryptases, and carboxypeptidases (Riley and West, 1953;
Hogan and Schwartz, 1997; Stevens and Adachi, 2007). Acti-
vated mast cells can also generate eicosanoids (leukotrienes and
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prostaglandins) by enzymatic biosynthesis from arachidonic acid
(Boyce, 2005). They can also synthesize and release a wide array
of cytokines, chemokines and growth factors, including but not
limited to IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, GM-CSF, TNF-α,
TGF-β, CCL2, CCL5, ﬁbroblast growth factor (FGF) and platelet
derived growth factors (PDGF; Burd et al., 1989, 1995; Plaut et al.,
1989; Lukacs et al., 1996; Kanbe et al., 1999; Oliveira and Lukacs,
2001; Artuc et al., 2002), which occurs over a longer time-frame of
hours rather than minutes, with the exception of TNF-α which
may be stored and released from granules (Gordon and Galli,
1990).
The wide array of mediators that can be released from mast
cells may be an indication of the versatility of mast cells and indi-
cate that theymay havemany distinct effector functions. However,
studyingmast cell function is challenging due to the rare nature of
the cells in circulation (particularly in healthy individuals) and the
difﬁculty of isolating mast cells without affecting their activation
state. In humans there are examples of rare disorders resulting
from enhanced mast cell mediator release, namely systemic mast
cell activation disease (MCAD). There are three forms of MCAD,
the most prevalent is mast cell activation syndrome (MCAS), fol-
lowed by systemicmastocytosis, thenmast cell leukemia (Haenisch
et al., 2012). Additionally,MCAS has been implicated as an under-
lying cause of ﬁbromyalgia (Lucas et al., 2006) and irritable bowel
syndrome (Frieling et al., 2011). There are however, no reports of
humans with mast cells deﬁciencies to aid in the deciphering of
their physiological roles in human physiology. In contrast, mast
cell-deﬁcient mouse strains have been used extensively to study
mast cell function. However, these strains generally have loss of
function mutations in the c-kit – SCF axis, complicating the pic-
ture with deﬁciencies in other c-kit expressing hematopoietic cells.
More recently, new mouse models have been developed and will
likely give a clearer picture of the functions unique to mast cells
(Reber et al., 2012).
Traditionally, mast cells are thought to have evolved to con-
fer protection against pathogens, particularly parasitic and fungal
infections (Abraham and St John, 2010). Carboxypeptidase3, a
mast cell product, can degrade the snake venom toxin safarotoxin
(Metz et al., 2006). Other characterized effects include protec-
tion against infections with gastrointestinal helminths as well
as acquired tick resistance (reviewed in Voehringer, 2013). In
addition to protection against infection, other physiological roles
for mast cells involving the regulation of the innate and adap-
tive immune system have been reported. These include tolerance
against skin graft rejection, angiogenesis, as well as tissue remod-
eling and wound healing (Gilﬁllan and Beaven, 2011). The role in
tissue repair and remodeling is described here, given the relevance
to the pathological role of mast cells in ﬁbrosis which is the main
subject of this review.
Upon injury, there are several stages of the wound healing
process; inﬂammation, ﬁbroblast migration/proliferation, and
remodeling. Although the pathogenesis of IPF is unclear, it is
thought to involve recurrent injury to the airway epithelium
and/or an aberrant wound healing response, and the stages of
ﬁbroblast proliferation/migration and tissue remodeling are par-
ticularly relevant to the ﬁbrotic process (Wynn, 2011). Although
studies of mast cell-deﬁcient mice have reported conﬂicting data
on the effect of mast cell deﬁciency on wound closure, most stud-
ies reported that mast cell depletion delayed, but did not prevent,
tissue repair and remodeling (Egozi et al., 2003; Iba et al., 2004;
Weller et al., 2006; Gallant-Behm et al., 2008; Shiota et al., 2010;
Younan et al., 2011; Antsiferova et al., 2013). There is evidence
that mast cells participate in multiple stages of the wound heal-
ing process (reviewed in Wulff and Wilgus, 2013). Within days
of injury, mast cells accumulate along the edges of the wound
(Trautmann et al., 2000). They likely contribute to local inﬂam-
mation by stimulation of vascular permeability through secretion
of histamine, lipidmediators, andVEGF,aswell as through recruit-
ment of other cell types (e.g., neutrophils via chymase; Dvorak,
2005; Weller et al., 2006; Takato et al., 2011). Although there are
other aspects of wound healing (e.g., apoptosis) the processes of
repair and remodeling are particularly relevant to ﬁbrosis. Mast
cells have been shown to stimulate the migration and prolifera-
tion of ﬁbroblasts (Levi-Schaffer and Kupietzky, 1990), a key cell
type in the proliferative phase of the wound healing process. These
effects aremediated at least in part by cytokines and growth factors
released by mast cells, including keratinocyte growth factor epi-
dermal growth factor and platelet-derived growth factor (PDGF;
Artuc et al., 1999, 2002; Noli and Miolo, 2001; Voehringer, 2013),
as well as histamine and tryptase (described in more detail below;
Levi-Schaffer and Piliponsky, 2003).
MAST CELL PRODUCTS AS MEDIATORS OF REMODELING
Many of the mast cell products described above as mediators of
normal physiological processes, if released in excess, can trigger
allergic and anaphylactic responses, and therefore also contribute
to a well characterized pathological role for mast cells. In con-
trast to this well-established role of mast cells in acute allergy and
anaphylaxis, their role in diseases involving chronic remodeling
processes is much less clear. Several mast cell products are pro-
ﬁbrotic including TGF-β, IL-13, CCL2, CCL5, IL-4, PDGF, and
FGF (and this list is not exhaustive). The roles of some of these
mediators in ﬁbrotic processes are described in more detail below.
TGF-β
Although mast cells are not the sole source of TGF-β1, this
pleiotropic cytokine is perhaps the most well characterized pro-
ﬁbrotic mediator produced by mast cells. TGF-β has multiple
functions that contribute to its role in ﬁbrosis, including actions
upon ﬁbroblasts and myoﬁbroblasts, key cell types involved in the
pathogenesis of ﬁbrosis. For example, TGF-β promotes ﬁbroblast
migration and proliferation (Postlethwaite et al., 1987), as well as
collagen formation and ﬁbroblast differentiation into myoﬁbrob-
lasts (Fine andGoldstein, 1987; Goldstein et al., 1992; Desmouliere
et al., 1993). Studies also suggest a role in epithelial–mesenchymal
transition (EMT;Willis et al., 2005).
TRYPTASE/CHYMASE
Mast cell proteases tryptase and chymase have effects on both the
connective tissue cells involved in ﬁbrosis as well as the surround-
ingECM.Theseproteases stimulate proliferationof airway smooth
muscle cells, epithelium and ﬁbroblasts, as well as ﬁbroblast
chemotaxis and myoﬁbroblast differentiation (Ruoss et al., 1991;
Brown et al., 1995; Cairns and Walls, 1996; Gruber et al., 1997).
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Mast cell tryptase can also stimulate the synthesis of type I collagen
by ﬁbroblasts (Cairns and Walls, 1997; Gruber et al., 1997), how-
ever, both proteases can also activate matrix metalloproteinases,
and may therefore increase turnover of the ECM (Tchougounova
et al., 2005; Iddamalgoda et al., 2008). Tryptase-mediated stimula-
tion of ﬁbroblast proliferation occurs via activation of the protease
activated receptor PAR-2 (Akers et al., 2000), and more recently
a PAR-2 dependency has also been demonstrated for tryptase-
induction of collagen and ﬁbronectin synthesis by ﬁbroblasts
(Wygrecka et al., 2013). Furthermore, these authors hypothesized
that the increase in PAR-2 expression observed in lung ﬁbroblasts
from patients with IPF could sensitize these cells to the effects of
mast cell-derived tryptase (Wygrecka et al., 2013).
IL-13
The Th2 cytokine IL-13 is a pro-ﬁbrotic mediator that is thought
to promote ﬁbrosis via TGF-β-dependent and independent mech-
anisms. IL-13 can induce TGF-β production and activation in vivo
and in human airway ﬁbroblasts and this is thought to involve
remodeling through IL-13Rα2 (Lee et al., 2001; Fichtner-Feigl
et al., 2006; Firszt et al., 2013). IL-13 can also directly promote
ﬁbrosis by stimulating proliferation or collagen production by
ﬁbroblasts as well as differentiation into myoﬁbroblasts (Oriente
et al., 2000; Saito et al., 2003; Ingram et al., 2004).
CC CHEMOKINES
CCL2 is a chemokine that signals through the receptor CCR2.
In addition to displaying chemotactic activity for immune cells
such as monocytes, a role in ﬁbrosis is suggested by the ability to
attract ﬁbrocytes to the airways following lung injury (Kay, 2005).
Furthermore, CCL2 can stimulate ﬁbroblast collagen production
via up-regulation of TGF-β expression (Holgate, 2008). The inter-
play between TGF-β, IL-13, and CCL2 in the context of ﬁbrosis
is discussed in more detail in (Manuyakorn et al., 2013). As well
as being synthesized by mast cells (Lukacs et al., 1996), CCL5 also
acts as a mast cell chemoattractant (Mattoli et al., 1995). While
the role of CCL5 as a ﬁbrotic mediator is less clear compared to
that of CCL2, there is some evidence that antagonism of CCL5
may be therapeutic in liver ﬁbrosis, possibly through the modula-
tion of monocyte subpopulations (Berres et al., 2010; Stock et al.,
2013).
MAST CELLS IN DISEASE
Mast cells are key contributors to multiple diseases in which there
is an element of tissue remodeling, of which asthma and atopic
dermatitis are two.
ASTHMA
Asthma is traditionally an inﬂammatory airway disease where
patients presentwith airﬂowobstruction causedby airwaynarrow-
ing, an increase cellular inﬁltrate (eosinophils, neutrophils, T cells)
to the lung and mucus plugging of the airways. The inﬂamma-
tion is typically Th2 driven and eosinophilic (Kay, 2005) involving
many of themediatorsmentioned previously. These are useful dis-
ease indictors to guide treatment; however this mechanism does
not explain all aspects of asthma. There are fundamental structural
changes in the asthmatic lung. The inability of anti-inﬂammatory
treatments to reverse symptoms or the decline in lung function
(Holgate, 2008) in some asthmatics is suggestive of a mechanism
of uncontrolled airway remodeling signiﬁcantly contributing to
disease pathology (Manuyakorn et al., 2013).
Many structural changes occur in asthma, including epithe-
lial shedding, enlarged submucosal glands, subepithelial basement
membrane thickening and ﬁbrosis as well as increased smooth
muscle (Manuyakorn et al., 2013). The most striking change is in
the smooth muscle which increases in amount by hyperplasia and
hypertrophy, as well as spreading up and down the airway (James
and Carroll, 2000), a mechanism for which remains unknown
(James et al., 2005). Increasing smooth muscle contributes to air-
way wall thickness which is also driven by deposition of extra
cellular matrix including collagen (Black et al., 2003; Howarth
et al., 2004).
Mast cells have been shown to be increased in asthma
(Dougherty et al., 2010; Andersson et al., 2011b). In the lung the
predominant mast cell is MCT (Irani et al., 1986), however MCTC,
normally present in low numbers, increase with asthma severity
(Balzar et al., 2011). The normal and asthmatic airways contain
similar numbers of mast cells in the submucosal connective tis-
sues, however there are increased mast cells in the epithelial layer
and smooth muscle (Brightling et al., 2002; Kaur et al., 2006), as
well as the bronchoalveolar lavage (BAL) ﬂuid of patients with
asthma (Shindoh et al., 1987). Increasedmast cell mediators in the
BAL ﬂuid (Gibson et al., 1993) support the theory of increased
presence but also increased reactivity of asthmatic mast cells over
non-asthmatic mast cells. The IL-33/ST2 axis has proved to be key
in mast cell biology. Mast cells are one of the highest ST2 express-
ing hemopoietic cell types (Moritz et al., 1998), ST2 is the receptor
for the IL-1 family member, IL-33 (Schmitz et al., 2005). IL-33 is
an alarmin released upon cell injury (Enoksson et al., 2011) and
could therefore play a critical role in wound healing and remod-
eling. Both IL-33 and ST2 have been shown to be upregulated in
asthma (Prefontaine et al., 2009).
The relationship between smooth muscle hyperplasia, ﬁbrosis,
and mast cells is unknown although it can be speculated that SCF
producing smooth muscle cells sustain mast cell survival (Page
et al., 2001), and in turn mast cells mediators such as tryptase
(Brownet al., 1995) andhistamine (Hollins et al., 2008) coulddrive
this phenomenon.
ATOPIC DERMATITIS
Atopic dermatitis (AD) is a chronic allergic inﬂammatory disease
affecting both children and adults in which mast cells are thought
to be a key cell driving the immune response. The main symp-
tom, pruritis (chronic itching) causes breakdown of the dermal
barrier allowing the opportunity for bacterial entry and colo-
nization of skin lesions, persistent inﬂammation, remodeling and
ﬁbrosis.
Many mediators, including histamine and Th2 cytokines that
have been reported to be pro-ﬁbrogenic and released from mast
cells, are involved in AD (Greaves and Khalifa, 2004; Darsow et al.,
2012; Metz et al., 2013). Additionally evidence is emerging for a
role for IL-33/ST2 axis in AD (Cevikbas and Steinhoff, 2012).
There appears to be two phases of the disease which progress
with severity as well as remodeling withmatrix deposition causing
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toughening/ﬁbrosis of the skin (Hamid et al., 1994). Mast cells are
reportedly more activated and undergoing degranulation in mild
disease, and increased numbers are associated with severe disease
(Hamid et al., 1994). There is evidence of a mast cell switch from
a MCTC phenotype (predominant subtype in the skin) to MCT
mast cells (Irani et al., 1986).
ROLE FOR MAST CELLS IN RENAL AND LUNG FIBROSIS
RENAL FIBROSIS
An association between mast cell recruitment/inﬁltration and
ﬁbrotic diseases has been reported in a number of organs to date.
Mast cells are elevated in various kidney disorders, in which the
ﬁbrosis is characterized by increased proliferation of ﬁbroblasts
and excessive accumulation of ECM (Silver, 2013). Mast cells have
been reported to play an integral part of the overall inﬂamma-
tory process and play a crucial role in interstitial ﬁbrosis in renal
amyloidosis (Toth et al., 2000). Liu et al. (2010) recently conﬁrmed
these ﬁndings, and suggested a role for SCF and PAR-2 inmast cell
recruitment and pathology. One study looking at a range of renal
diseases revealed that the degree of renal interstitial ﬁbrosis was
well correlated with the number of inﬁltrating tryptase-positive
mast cells (Kondo et al., 2001).
In experimental models, mast cells have been reported to
be crucial to renal ﬁbrosis induced by ureteral obstruction
(Holdsworth and Summers, 2008), supporting the ﬁndings from
Veerappan et al. (2012) reporting that mast cells are required
for the development of renal ﬁbrosis in the rodent unilat-
eral ureteral obstruction model. These reports show causality
for mast cells in experimental renal ﬁbrosis and support clin-
ical ﬁndings correlating mast cell numbers and the degree of
ﬁbrosis obstruction (Holdsworth and Summers, 2008). Addition-
ally, the mast cell remodeling sodium chromoglycate has been
reported to attenuate renal ﬁbrosis (Summers et al., 2012), there-
fore it is proposed that pro-ﬁbrotic mediators released via mast
cell degranulation drive ﬁbroblast activation and proliferation,
and therefore targeting this cell type in renal disease could be
attractive.
The concept of mast cells in pulmonary ﬁbrosis is not a new
one. Indeed, in the late ‘80s, and early ‘90s, a number of labo-
ratories identiﬁed an increase in mast cells, or their products, in
the lungs of IPF patients. In 1986, Rankin and colleagues com-
pared the levels of histamine, a known mast cell product, in the
BAL ﬂuid of normal patients versus IPF, asthma, and sarcoidosis
and reported increased histamine in IPF samples only (Rankin
et al., 1987). In 1987, Shindoh and colleagues reported that when
comparing basophilic cells (BCs) in the BAL ﬂuid from patients
with asthma and IPF, formalin-insensitive BCs, which were pre-
sumed to be CTMCs, were observed in BAL ﬂuids from IPF
patients whereas basophils were the major components of BCs in
asthmatic patients. These compared to control subjects in which
almost all of BCs were MMCs (Shindoh et al., 1987). In 1990,
Fortoul and colleagues compared the number of mast cells in the
lungs of IPF vs non-ﬁbrotic lung disease vs normal, ﬁnding an
approximate 10-fold increase in interstitial mast cells compared
with the non-ﬁbrotic patients, whereas the mast cell levels were
almost equal in both groups of patients in the subpleural, peri-
bronchiolar, and perivascular areas (Fortoul and Barrios, 1990).
In 1990, Hunt and co-workers also quantiﬁed mast cells in the
peribronchiolar tissue of IPF and normal human lung by using
rabbit antiserum to human mast cell tryptase. They reported over
a twofold increase in the connective tissue directly adjacent to the
lumen of small airways and other ﬁbrotic foci in IPF versus con-
trol lungs,which appeared tobe actively degranulating (Hunt et al.,
1992). In addition, Edwards et al. (2005) proﬁled c-kit expressing
cells in interstitial lung disease (including IPF), reporting elevated
c-kit+ mast cells both positive for the serine proteases chymase
and tryptase, as well as MMP expression in disease versus normal
lung environment. Pesci et al. (1993) did not include IPF in their
patient population, they did evaluate the numbers of mast cells
in the ﬁbrotic lung disorders in order to determine their role in
the pathogenesis of this disorder and reported a clear increase in
mast cell number which signiﬁcantly correlated with the degree
of ﬁbrosis. The presence of the mast cell mediator basic FGF has
also been evaluated in human interstitial lung disease to deter-
mine if mast cells and their contents drive the ﬁbrotic response
(Inoue et al., 1993). Analysis of lung tissue, BAL ﬂuid, and serum
from patients with IPF detected increased bFGF+MC in the lung
interstitium, correlating with the distribution of ECM deposition
and the extent of ﬁbrosis morphometrically, as well as elevated
bFGF in the BAL ﬂuid (Inoue et al., 1993). Moreover, increased
levels of tryptase were measured in the BAL ﬂuid of IPF patients,
with tryptase-positive IPF cases reported to have a poorer outcome
(Kawatani et al., 2007).
More recently Andersson and colleagues investigated the dis-
tribution pattern and phenotypes of lung mast cells in ﬁbrosis-
related conditions. As detailed earlier, mast cell subtypes can be
broadly identiﬁed by their granule content, being either typtase
and chymase positive (MCTC or CTMCs), or tryptase positive
but chymase negative (MCT orMMCs). MMCs are most fre-
quently found in the healthy lung (Metcalfe et al., 1997). They
reported that a signiﬁcantly elevated number of TGFβ+ mast
cells in ﬁbrotic areas of the alveolar parenchyma in patients
with IPF, however no change was detected in the small airways
and were decreased in the pulmonary vessels. The authors also
reported an increase in mast cell expression of TGF-β in the
increased mast cells found in the alveolar parenchyma, and that
the density and percentage of MCTC correlated positively with
the degree of ﬁbrosis and negatively with patient lung function
(Andersson et al., 2011b). Increased activated mast cells were
also reported in close proximity to ﬁbroblast foci and alveo-
lar type II cells in the IPF lung, as well as elevated mast cell
tryptase in patients with IPF (Wygrecka et al., 2013). However,
Cha et al. (2012) recently reported that although chymase posi-
tive mast cells are elevated in IPF, this correlated with a slower
rate of decline in forced vital capacity suggesting a protective
mechanism.
A number of experimental animal studies have now been
reported to investigate the role mast cells play in the lung,
typically using mast cell-deﬁcient strains genetically engineered
through a genetic deﬁcient in c-kit. Early studies in WBB6F1-
W/Wvmice reported bleomycin-induced ﬁbrosis regardless of the
mast cell deﬁciency (Mori et al., 1991). Additionally bleomycin
could induce ﬁbrosis using Ws/Ws mast cell-deﬁcient rats to
a similar extent as that observed in wild types (Okazaki et al.,
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1998). However, more recently Veerappan et al. (2013) reported
a pivotal role of mast cells in the initiating lung ﬁbrosis. In this
study, the authors administered bleomycin to mast-cell-deﬁcient
WBB6F1-W/Wv mice and their respective controls and demon-
strated a protection, which was lost post restoration of the mast
cell population (Veerappan et al., 2013). The authors postulate
that the protective effects seen in their studies compared to
the earlier studies (Mori et al., 1991; Okazaki et al., 1998), may
be due to differences in experimental protocol (theirs being a
2 week model vs a 5 week model used by others). In a recent
pharmacological study, berberine, a plant alkaloid was given to
mice exposed to bleomycin. In this study, bleomycin induced
mast cell accumulation in the lung and increased histamine
levels. Berberine signiﬁcantly blocked collagen accumulation as
observed by a reduction in the hydroxyproline level, which cor-
responded with reduced histamine levels (Chitra et al., 2013),
supporting a role for mast cell in the pathogenesis of lung
disease.
The underlying mechanism for increased mast cells in IPF
remains unknown, however a role for SCF is emerging. SCF is
expressed as soluble or membrane-bound forms and promotes
survival, proliferation, mobilization from the bone marrow and
adhesion of hematopoietic stem cells and other progenitor cells
through binding with its receptor, c-kit (Fleming et al., 1993;
Lukacs et al., 1996; Domen and Weissman, 2000; Nakamura et al.,
2004). In the lung this axis has been shown to be important in
ﬁbrosis as suggested by increased secretion of SCF from alveolar
ﬁbroblasts from patients with diffuse interstitial ﬁbrosis (Fireman
et al., 1999). In a mouse model of cockroach induced asthma,
blockade of SCF has been shown to attenuate airway remodeling
and collagen deposition in the lung (Dolgachev et al., 2009). In IPF,
Wygrecka and colleagues demonstrated increased expression of
membrane SCF in the IPF lung and in ﬁbroblasts isolated from IPF
tissue. Co-culture of lung ﬁbroblasts from IPF patients with mast
cells enhancedMC survival and proliferation, an effect dependent
on SCF and c-kit (Wygrecka et al., 2013). This phenomenon has
also been reported elsewhere, whereby SCF expressed on bronchial
airway smooth muscle induces the survival, proliferation and
activation of lung mast cells (Hollins et al., 2008). Additionally,
blockade of SCF either genetically or using an antibody approach
abrogates bleomycin-induced lung ﬁbrosis, although mast cell
measurements were not made in this model (Ding et al., 2013).
SUMMARY AND FUTURE CLINICAL DIRECTIONS
Idiopathic pulmonary ﬁbrosis is a devastating disease for the
patient. There is currently no effective treatment for this disease
and the prognosis is bleak. As the term “idiopathic” indicates, the
causes of the disease are unknown, as are the molecular mecha-
nisms underpinning initiation and progression of the condition.
Clearly, ﬁbrotic processes play a key role in driving the relentless
destruction of alveolar integrity, resulting eventually in a declining
ability of the lung to oxygenate the blood. This decline is the root
cause of the deteriorating health of the patient once the disease
passes from its typically undiagnosed, early phase, into its clini-
cally symptomatic phase.Within less than 3 years in most patients
have lost much of their respiratory capacity and require drastic
measures to survive.
The pharmaceutical and biotechnology industry has made
many attempts to ﬁnd effective treatments for IPF, but the disease
has so far deﬁed all attempts at therapeutic intervention. Clinical
trial failures may arise for many reasons, including disease hetero-
geneity, lack of readily measurable clinical end points other than
overall survival, and, perhaps most of all, a lack of understand-
ing of the underlying molecular mechanisms of the progression
of IPF.
On the positive side, with emerging new insights into the path-
ways and cell types involved in IPF come new opportunities for
therapeutic intervention. Technologies for molecular proﬁling of
patient tissue samples are already revealing many hitherto unex-
pected aspects of the disease pathology. Several new cell types,
including the myoﬁbroblast and the mast cell, offer therapeutic
possibilities not previously exploited. However, the only conclusive
way to determine if these cells are important for the pathogene-
sis of IPF is to target them with sufﬁciently powerful therapeutics
and determine the impact on disease progression in phase 2 clin-
ical trials. Another potentially helpful way to success may be that
new therapeutics are ﬁrst tested in other ﬁbrotic conditions than
IPF. Based on our current understanding of disease mechanisms,
it appears likely that therapeutic interventions that are efﬁcacious
in one form of ﬁbrotic disease will be efﬁcacious in other ﬁbrotic
conditions. Thus, the clinically most feasible disease indication
may serve as a ﬁrst read-out to support the testing in more chal-
lenging indications, such as IPF. This may well be the case for mast
cell-targeted therapies. We postulate that this hypothesis should
be tested.
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